Press review


French pharmacovigilance managers concerned about planned shake-up

PARIS, 14 June (APM) - French pharmacovigilance managers are worried about government plans to restructure the system, reported Le Monde Science & Medecine on Wednesday (p1 and 4-5).
A draft decree, presented to managers of pharmacovigilance centres after two years of negotiation, sets out plans to reform the whole system to make it more efficient. However, the pharmacovigilance managers fear they are too much administrative.

French pharmas' revenue down 16% since 2010

French pharmas' revenue has fallen 16% since 2010 because of price reductions, reported Les Echos (p19) and Le Figaro (p26) on Thursday.
Their cumulative revenue is now €4.5 billion, according to a report from French pharma lobby G5 santé (APMHE 63319).
The future framework agreement for the coming three years is currently being negotiated between the country's Healthcare Products Pricing Committee, CEPS and French pharma industry body LEEM.

Dassault Systèmes buys Medidata

Dassault Systèmes is buying U.S. digital life sciences platform specialist Medidata for $5.8 billion, Le Figaro (p27), Les Echos (p21 and 32), and La Croix (p10) reported on Thursday (APMHE 63308).
This is the biggest purchase by Dassault Systèmes. Some 13 of the top 15 drugs sold in 2018 included Medidata's technology in their development.

Paul Hudson appointed Sanofi CEO

Paul Hudson has been appointed the new chief executive of Sanofi, Les Echos (p20) announced on Tuesday (APMHE 63257).
Hudson head of Novartis' pharmaceutical division, will succeed Olivier Brandicourt in September.

Insys files for bankruptcy

U.S. firm Insys has filed for bankruptcy, Libération (p11) reported on Tuesday (APMHE 63290).
Insys, involved in the U.S. opioid scandal, is seeking protection amid mounting expenses driven by a U.S. Justice Department probe into claims it paid doctors bribes to prescribe a powerful opioid medication.

Report on Levothyrox by the France's drugs' regulator ANSM

A report from France's drugs' regulator ANSM concluded that the new version of Merck KGaA's Levothyrox (levothyroxine) does not lead to serious health issues, reports 20 minutes on Friday.
Based on a retrospective review of two million patients, this report was published on Thursday.

French homeopathy specialist Boiron counter attacks

France's homeopathy specialist Boiron has counter attacked to defend the reimbursement of homeopathy to France's healthcare technology assessment body HAS, reported La Croix (p8) on Wednesday.
For several months, the group has tried to influence the decision with a large promotion campaign.
A hearing with the assessment body was planned on 12 June. The final notice from the HAS should be published on 28 June.

AmyPore develops new therapeutic pathway for Alzheimer's disease

French biotech AmyPore has developed a new therapeutic pathway for Alzheimer's disease, linked to a chimeric peptide, Les Echos (p30) reported on Tuesday.
The company has been selected for the Horizon 2020 programme of the European Commission.

Yukin Therapeutics raises €3.3 million

French start-up Yukin Therapeutics, specialising in the development of new molecules for cancer treatment, has raised €3.3 million, Les Echos (p25) reported on Thursday.
The new funding came from Advent France Biotechnology, its main shareholder and the international investment fund Medicxi.



Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations

Events coverage with a unique focus on Market Access & sustainability of healthcare systems

6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris

Ask for a Free trial and get access to the latest stories

Our coverage includes:
  • Health Care
  • Market Access
  • HTA – policies & practices
  • European medicine regulations
  • Drug safety issues
  • Pricing & Reimbursement
  • International medicines agencies

If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.


an initial 10 day temporary access of APM Health Europe.